Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Marvel Biosciences Corp ( (TSE:MRVL) ) is now available.
Marvel Biosciences Corp. plans to raise up to $500,000 through a non-brokered private placement of unsecured convertible debentures, subject to TSX Venture Exchange approval. The debentures will carry 12% annual interest, mature on December 31, 2027, and may be converted into common shares at $0.12 per share, with the company able to force conversion if its stock trades at or above $0.60 for 10 consecutive trading days.
The company intends to use the net proceeds for drug formulation, toxicology studies and general working capital, supporting advancement of its lead neurological candidate MB-204. Marvel has set ownership caps on debenture conversion to prevent any single investor from exceeding 10% of its voting securities, and it will not pay commissions or finder’s fees on the offering, underscoring a tightly structured capital raise aimed at funding its pre-clinical pipeline.
The most recent analyst rating on (TSE:MRVL) stock is a Hold with a C$0.17 price target. To see the full list of analyst forecasts on Marvel Biosciences Corp stock, see the TSE:MRVL Stock Forecast page.
Spark’s Take on MRVL Stock
According to Spark, TipRanks’ AI Analyst, MRVL is a Neutral.
The score is weighed down primarily by weak financial performance (no revenue, ongoing losses, negative equity, and continued cash burn). Technicals are moderately supportive in the near term (price above key short/mid-term averages with neutral momentum), but valuation remains constrained due to negative earnings and no dividend yield.
To see Spark’s full report on MRVL stock, click here.
More about Marvel Biosciences Corp
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical biotechnology company. It is developing MB-204, a novel fluorinated derivative of anti-Parkinson’s drug Istradefylline, targeting the adenosine A2a receptor for potential treatment of Parkinson’s and other neurological and neurodevelopmental disorders, including autism, depression, Alzheimer’s, Rett Syndrome and Fragile X Syndrome.
Average Trading Volume: 57,647
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$9.57M
For a thorough assessment of MRVL stock, go to TipRanks’ Stock Analysis page.